KEE Targeting 3.0: Beyond Lists, Beyond Channels, Beyond Assumptions
KEE targeting has evolved. Version 1.0 was spreadsheets of “top names.” Version 2.0 chased digital activity, who posts, where, and […]
Advanced Segmentation: From Role to Impact in KEE Targeting
Not all influence looks the same. Some experts write guidelines, others steer trial sites, and a growing cohort shapes thinking
Strategic Silence: Why the Most Impactful Experts Aren’t Always the Most Vocal
Volume isn’t the same as influence. Some Key External Experts shape clinical thinking without posting daily threads or dominating conference panels. They
Building an Expert Universe: Connecting the Dots Between Influence, Behavior & Reach
Identifying and engaging Key Opinion Leaders (KOLs) requires more than just counting followers or publication citations. With rapid digitalization and innovation in
Social Media to Strategic Plans: DOL Engagement That Works
Digital Opinion Leaders (DOLs) have emerged as critical partners for healthcare organizations seeking to amplify scientific insights, foster clinician trust,
Real-Time Social Listening for Competitive Strategy
Effective competitive strategy in healthcare hinges on timely, actionable insights. Traditional market research (sales data, prescription volumes, and clinical trial
The Underrated Power of KEE Sentiment in Shaping Brand Perception
Effective brand management in healthcare requires more than clinical data and sales metrics. Key Opinion Experts (KEEs), clinicians, researchers, and specialized practitioners
How KOL Mapping Strengthens Your Pre-Launch Strategy
In today’s competitive pharmaceutical landscape, a product’s success doesn’t start at launch—it begins long before. The launch strategy sets the
AI-Powered KOL Mapping: Scaling Engagement with Precision and Personalization
The way the competitive pharma industry is set up today, success doesn’t start post-launch; it starts well before launch. By
Mining the Right Insights: How Pharma Companies Can Leverage Data for Competitive Advantage
Imagine launching a new drug only to realize that it’s struggling in the market due to poor adoption by physicians